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Survival of melanoma patients after metastases detection remains short. Several clinical
trials have shown moderate efficiency in improving patient survival, and the search for phar-
macological agents to enhance the immune response and reduce melanoma metastases is
still necessary. Statins block the mevalonate pathway, which leads to decreases in GTPase
isoprenylation and activity, particularly those of the Ras superfamily. They are widely used
as hypocholesterolemic agents in cardiovascular diseases and several studies have shown
that they also have protective effects against cancers. Furthermore, we have previously
demonstrated that treatment of melanoma cells with inhibitors of the mevalonate path-
way, such as statins, favor the development of specific adaptive immune responses against
these tumors. In the present study, we tested statin impact on the innate immune response
against human metastatic melanoma cells. Our data shows that treatment of two human
melanoma cell lines with statins induced a weak but significant increase of MHC class I
Chain-related protein A (MICA) membrane expression. Peroxisome Proliferator-Activated
Receptor gamma is involved in this statin-induced MICA overexpression, which is indepen-
dent of Ras and Rho GTPase signaling pathways. Interestingly, this MICA overexpression
makes melanoma cells more sensitive to in vitro lysis by NK cells. The impact of statin
treatment on in vivo development of melanoma tumors and metastases was investigated
in nude mice, because murine NK cells, which express NKG2D receptors, are able to recog-
nize and kill human tumor cells expressing MICA.The results demonstrated that both local
tumor growth and pulmonary metastases were strongly inhibited in nude mice injected
with statin-treated melanoma cells. These results suggest that statins could be effective
in melanoma immunotherapy treatments.
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INTRODUCTION
Cutaneous melanomas are the most aggressive skin cancers. They
arise from melanocytes and, after horizontal and vertical growth,
extravasate into the draining lymph nodes and blood vessels, from
which they can metastasize. Patient survival following metasta-
tic detection is usually short. Therefore, current treatments target
metastatic growth. Inhibitors of BRAF mutated V600E were vali-
dated by several clinical trials but their efficiency is not long lasting
and is mostly restricted to BRAF V600E mutated tumors (Flaherty
et al., 2010; Weeraratna, 2012). Other treatments with antibodies
directed against the CTLA-4 molecule have shown efficiency in
metastatic melanoma (Hodi et al., 2010), but these antibodies can
also induce deleterious inflammation (Berman et al., 2010). Thus,
the search for pharmacological agents to enhance the immune
response to reduce melanoma metastases is still necessary.
Statins are used by millions of people as hypocholesterolemic
agents in cardiovascular and cerebrovascular diseases. Addi-
tionally, retrospective studies have shown that, besides this
hypocholesterolemic activity, statins can also have a protective
effect against the development of cancers, particularly melanomas
(Boudreau et al., 2010; Jacobs et al., 2011). Statins are HMG-
CoA reductase inhibitors, which block the mevalonate synthesis
pathway. By inhibiting this metabolic pathway, statins also inhibit
the activity of numerous GTPases of the Ras superfamily as they
require the isoprenoid chains, synthesized from the mevalonate,
for their function and localization (Rikitake and Hirata, 2009).
Statins also have pleiotropic effects, including the enhancement
of Peroxisome Proliferator-Activated Receptor gamma (PPARγ)
activities (Balakumar and Mahadevan, 2012). PPARγ is a tran-
scription factor that is overexpressed in several types of cancer
(Peters et al., 2012), particularly melanomas (Meyer et al., 2009).
We have previously shown that treatments of melanoma cells
with mevalonate pathway pharmacological inhibitors, notably
statins, and in combination with IFNγ favor the anti-tumor adap-
tive immune response by inducing MHC class I and costimulatory
molecule (CD80/CD86) overexpression (Tilkin-Mariame et al.,
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2005; Sarrabayrouse et al., 2010). We then asked the question
whether or not these inhibitors could also favor the anti-melanoma
innate immune response. We were particularly interested in NK
cells, which are among the most efficient effectors of the innate
immune system and also recognize several molecules expressed
on the surface of both stressed and tumor cells. A critical receptor
expressed on NK cells is the NKG2D activating receptor, which is
able to recognize tumor cells from murine or human origin (Cer-
wenka and Lanier, 2001; Fuertes et al., 2008). On tumor or stressed
cells, this type II transmembrane receptor recognizes ligands, such
as UL-Binding Proteins (ULBPs) and MHC class I Chain-related
protein A (MICA) and B (MICB), all related to the MHC class
I molecules (Lanier, 2008). NKG2D expression is essential for
NK cell control of tumor development, as illustrated by NKG2D-
KO mice, which develop numerous tumors and die prematurely
(Guerra et al., 2008).
In the present study, we analyzed statins’ ability to regulate
MICA expression in human melanoma cells and the consequences
of this treatment on melanoma development. We demonstrated
that treatment of two human melanoma cells with atorvastatin
or lovastatin induced a weak but reproducible MICA membrane
overexpression, provoking an increase of melanoma cell sensitivity
to NK cell lysis in vitro. Moreover, we observed in vivo that ator-
vastatin pretreatment of these melanoma cells strongly reduced
both local melanoma growth following subcutaneous injection
as well as pulmonary metastases implantation after intravenous
injections. This data suggests that statins could be interesting
pharmacological inhibitors for melanoma immunotherapy as they
favor the innate immune response against tumor cells.
RESULTS
STATIN TREATMENT INDUCES MICA OVEREXPRESSION AND
INCREASES MELANOMA SENSITIVITY TO NK-KILLING
We tested whether treatment of human melanoma cells with
statins could render these cells more immunogenic and more
sensitive to NK cell destruction. LB1319-MEL human melanoma
cells were treated for 48 h with 5µM atorvastatin. This treat-
ment induced a 2.2-fold total MICA protein enhancement
(Figure 1A) and also weakly enhanced MICA membrane expres-
sion (Figures 1B,C), but not the deleterious cleavage of membrane
expressed MICA (Figure 1D). The 5µM dose of atorvastatin for
48 h was chosen after dose-response experiments as illustrated in
Figure A1A in Appendix. This atorvastatin treatment is not toxic
to LB1319-MEL cells, as their in vitro proliferation rate following
treatment is still similar to the control (Figure 1E). Similar results
were obtained with another human melanoma cell line, BB74-
MEL, which was treated with atorvastatin at 5 or 10µM. Similar to
LB1319-MEL cells, the BB74-MEL cells also exhibited weak mem-
brane MICA overexpression in response to statins (Figure A1B in
Appendix) without increasing the cleavage of membrane expressed
MICA (Figure A1C in Appendix) or toxicity (Figure A1D in
Appendix).
Recent studies showed that the increase of MICA and MICB
expression on target tumor cells induced an increase in sensi-
tivity to lysis by NK cells (Zhang et al., 2009; Chavez-Blanco
et al., 2011). We therefore tested whether or not atorvastatin
plays a role in increasing the sensitivity of melanoma cells to NK
cell-mediated death. We isolated fresh NK cells from C57BL/6
splenocytes using magnetic cell separation (Miltenyi Biotec) and
cocultivated them for 1 h with LB1319-MEL target cells either
untreated or pretreated with atorvastatin. FACS analysis of tumor
cell lysis showed that atorvastatin treatment induced a twofold
increase in LB1319-MEL cell death as compared to untreated
target cells (Figure 1F). In this experiment, corresponding to pre-
viously shown data, murine NK cells were able to recognize and
kill human target cells by interaction of their NKG2D receptors
with specific ligands expressed on human target cells, such as
MICA, MICB, and ULBP (Cerwenka and Lanier, 2001; Fuertes
et al., 2008).
To test whether another statin could also induce MICA mem-
brane overexpression, LB1319-MEL cells were treated with 1µM
lovastatin for 48 h and MICA expression was analyzed by flow
cytometry. The 1µM dose of lovastatin was chosen after dose-
response experiments as illustrated in Figure A1E in Appen-
dix. Similarly to atorvastatin, lovastatin induced a weak MICA
membrane overexpression (Figure 1G).
Altogether, this data shows that statin treatment of human
melanoma cells enhanced MICA protein and membrane expres-
sion and that these treatments were not toxic, but increased the
sensitivity of the tumor cells to NK-induced cell death in vitro.
ATORVASTATIN TREATMENT OF LB1319-MEL CELLS SLOWS TUMOR
GROWTH AND REDUCES METASTATIC PULMONARY IMPLANTATION
Based on our in vitro conclusions, we wondered if atorvastatin
treatment of melanoma cells could increase sensitivity to the
anti-tumor innate immune response in a mouse model. In sum-
mary, we performed subcutaneous injections of LB1319-MEL
cells, either untreated or pretreated with 5µM atorvastatin for
48 h, into the flank of nude mice. We were not able to perform
this assay with BB74-MEL cells, as they do not grow in the nude
mice. The resulting tumors showed that LB1319-MEL cells pre-
treated with atorvastatin grew drastically (p< 0.005) slower than
untreated cells (Figure 2A). Interestingly, two mice among the six
injected with pretreated LB1319-MEL cells rejected their tumor
(Figure 2C), whereas no rejection was observed among the mice
injected with untreated LB1319-MEL cells (Figure 2B). These
results are consistent with the statin-induced MICA overexpres-
sion and enhancement of in vitro tumor cell death by NK cells.
Furthermore, we used two other human melanoma cell lines:
LB2033-MEL and LB583-MEL. These cells are MICA negative
and remained negative following atorvastatin treatment as illus-
trated in Figure A2A in Appendix. We injected subcutaneously
these melanoma cells either untreated or pretreated, as LB1319-
MEL, with 5µM atorvastatin. The resulting tumors showed that
negative MICA cells both pretreated and untreated grew simi-
larly (Figures A2B,C in Appendix). These results confirmed the
involvement of statin-induced MICA overexpression in the tumor
growth.
We also tested the effect of atorvastatin treatment on the in vitro
migration of the LB1319-MEL cells. We did not observed any sig-
nificant difference between the migration of treated and untreated
cells (Figures A2D,E in Appendix). This data suggested that the
atorvastatin-induced slow-down of in vivo tumor growth is not
linked to an inhibition of tumor cells migration.
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FIGURE 1 | Statin treatment induces MICA overexpression and increases
NK-dependent cytotoxicity. LB1319-MEL cells were treated with 5µM
atorvastatin for 48 h (Ator) or untreated (H2O). The atorvastatin treatment
efficiency was controlled by the analysis of Rap1A unprenylation (Rap1A u.p)
compared to the total protein (Rap1A total) (A). MICA total expression was
analyzed by western blot (A), membrane expression by flow cytometry (B,C),
and cleavage by ELISA (D) (n=3). To evaluate membrane antigen expression,
the index of specific fluorescence (ISF) was calculated as indicated in the
Section “Materials and Methods” (C). Results are expressed as mean±SD
[error bars, n= 5 experiments (C) or 3 experiments (D)]. *P <0.5; versus
control condition using the Student t -test. Every 2–3 days pretreated (Ator)
and untreated (H2O) LB1319-MEL cells were counted to evaluate the in vitro
proliferation (E). ns; versus control condition using the two-way ANOVA test.
Percentage of lysed LB1319-MEL cells pretreated (Ator) or untreated (H2O)
after coculture with murine NK cells was evaluated with Cytoxilux kit
(Onco-immumin, Interchim). Murine NK cells were first isolated from three
C57BL/6 spleens with CD49b MicroBeads (Miltenyi Biotec) (F). ***P <0.001;
versus control condition using the two-way ANOVA test. LB1319-MEL cells
were treated with 1µM lovastatin for 48 h, and MICA membrane expression
was analyzed by flow cytometry (G).
As NK cells play an important role in the control of metasta-
tic processes (Mehlen and Puisieux, 2006), we assessed whether
statin-induced MICA overexpression and subsequent sensitiv-
ity to the innate immune response could reduce the metastatic
processes, more specifically the final step of pulmonary implan-
tation. LB1319-MEL cells either untreated or pretreated with
5µM atorvastatin were injected intravenously into the tail vein
of nude mice and the animals were sacrificed 16 days later.
Thirty hours before sacrifice, the tumor and neoangiogenesis
sensor IntegriSense was injected intravenously (Kimura et al.,
2009; Mery et al., 2011; He et al., 2012; Valdivia et al., 2012).
This fluorescent reagent allowed visualization and quantifica-
tion of tumor implantations and neoangiogenesis in the lungs
(Figures 2D,E). We observed that untreated LB1319-MEL cells
colonized the lungs and induced a considerable neoangiogene-
sis, while atorvastatin-treated LB1319-MEL cells were less invasive
with strongly decreased neoangiogenesis.
These results showed that statin pretreatment of melanoma
cells reduced in vivo tumor development and metastasis.
INHIBITION OF GTPases OF Ras SUPERFAMILY DOES NOT INDUCE
MICA OVEREXPRESSION
Proteins of the Ras superfamily play regulatory roles on essential
cellular functions (Heasman and Ridley, 2008). Their activity can
be blocked by statin treatment, because statins block mevalonate
production by HMG-CoA reductase and consequently inhibit
the production of isoprenyl PyroPhosphates (PP), geranyl PP,
and farnesyl PP, which are the precursor molecules necessary
to produce isoprenoid chains. These isoprenoid chains bind to
the carboxy-terminal end of Ras superfamily proteins and allow
adequate cellular localization and activity. To explain why statin
treatment induced MICA overexpression, we hypothesized that
statin could block a negative regulator of MICA expression. These
negative regulatory proteins, blocked by statin treatment, could be
isoprenylated proteins of the Ras superfamily.
We first tested the involvement of proteins of the Rho GTPases
subfamily. The three highly related Rho isoforms, RhoA, B, and
C share some effector proteins, but also show clear functional
differences (Heasman and Ridley, 2008). To determine whether
these Rho GTPases are involved in the regulation of MICA mem-
brane expression, we used a bacterial inhibitor of RhoA, B, and
C (Tat-C3 exoenzyme), which inhibits the Rho proteins activity
by inducing ADP-ribosylation of these three GTPases. The results
showed that treatment of LB1319-MEL cells with Tat-C3 actu-
ally induced downregulation of MICA rather than the expected
increase (Figures 3A,B). Therefore, these Rho proteins effectively
regulate MICA expression but in a positive way. We then used a
siRNA strategy that allows the specific inhibition of RhoA, RhoB,
or RhoC, to test whether one of them could behave differently and
negatively regulate MICA expression. We first verified that these
siRNAs were efficient in reducing RhoA, RhoB, or RhoC protein
expression (Figures A3A–C in Appendix) and then tested their
impact on MICA expression. Transfection of two RhoA-specific
siRNAs in LB1319-MEL cells did not induce any modification
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FIGURE 2 | Atorvastatin treatment inhibits melanoma in vivo
development and metastasis. LB1319-MEL cells untreated (H2O) or
pretreated with atorvastatin 5µM for 48 h (Ator) were injected
subcutaneously into the flank of six nude mice. Tumor growth was
measured every 2–3 days (A). ***P <0.001; versus control condition
using the two-way ANOVA test. Tumor growths for each mice are
represented (B,C). LB1319-MEL cells untreated (H2O) or pretreated with
5µM atorvastatin for 48 h (Ator) were injected intravenously. Fifteen
days later IntegriSense was intravenously injected and the mice were
sacrificed 30 h later. The lungs appeared fluorescent and the IntegriSense
fluorescent signal was analyzed by Fluobeam®camera. The image is
representative of one experiment (D). The fluorescent signal was
quantified (E). ***P <0.001; versus control condition using the Student
t -test.
of MICA expression (Figure 3C), while cells transfected with
RhoB- or RhoC-siRNAs significantly reduced MICA expression as
compared to siCtrl (Figures 3D,E). Consequently, these Rho pro-
teins cannot be responsible for the increased expression of MICA
induced by statin treatment.
We then tested the impact of siRNA-induced reduction of
Rac1 and Cdc42, two other essential members of the Rho fam-
ily. These proteins are known to be involved in the regulation of
several cellular functions, including migration and gene transcrip-
tion (Heasman and Ridley,2008). SiRNA transfections successfully
inhibited Rac1 and Cdc42 expression (Figures A3D,E in Appen-
dix). We observed that Cdc42 inhibition had no statistical effect on
MICA expression, while Rac1 inhibition actually reduced MICA
expression in LB1319-MEL cells (Figures 3F,G). Altogether, these
results show that these Rho proteins are not responsible for the
statin-induced overexpression of MICA.
Next, we investigated the role of Ras proteins in statin-induced
MICA overexpression. Ras GTPase activities can be inhibited by
statin treatment, because these proteins need to be farnesylated
on their C-terminal end for membrane anchorage and activity.
To determine whether Ras proteins are involved in MICA overex-
pression, we used a biochemical inhibitor of Ras protein activity
(S-FarneylThioSialicylic acid, FTS). The results showed that inhi-
bition of Ras protein activity by FTS (50–100µM for 24 h) also
induced a decrease in MICA expression (Figures 3H,I). There-
fore, Ras proteins are not responsible for statin-induced MICA
overexpression.
PPARγ AND SAPK/JNK INVOLVEMENT IN STATIN-INDUCED MICA
OVEREXPRESSION
As it is known that statins may affect the PPARγ pathway (Bal-
akumar and Mahadevan, 2012), we checked the involvement
of this factor in the statin-induced MICA overexpression. As
shown in Figures 4A,B, treatment of the LB1319-MEL cells with
T0070907, a specific inhibitor of the PPARγ pathway, led to a
weak but significant and reproducible decrease of the membrane
MICA expression. Additionally, transfection of an expression vec-
tor encoding a dominant negative mutant of PPARγ (PPARγ DN)
had a similar effect (Figures 4C,D). Furthermore, LB1319-MEL
cells transfected with a reporter vector containing three PPARγ
Responsive Element (PPRE) cloned upstream of a luciferase gene
(pGL4.3xPPRE-FLuc) exhibited a weak but significant increase
of the luciferase expression following 5µM atorvastatin treat-
ment (Figure 4E). The treatment of LB1319-MEL cells with
increasing doses of atorvastatin, from 0.3 to 10µM, confirmed
this data (Figure A4A in Appendix). Finally, CPT1A mRNAs
were increased in LB1319-MEL cells following 5µM atorvas-
tatin treatment (Figure A4B in Appendix). This data confirm
the involvement of PPARγ pathway since CPT1A is a target
gene for PPARγ (Heinaniemi et al., 2007; Szatmari et al., 2007;
Sharma et al., 2012). Therefore, it is possible that statins activate
the PPARγ pathway, leading to downstream increases in MICA
expression.
To assess the possible involvement of other pathways, we then
performed a Human Phospho-Kinase Array (R&D systems). The
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FIGURE 3 | Inhibition of Rho and Ras GTPases proteins do not induce
MICA membrane overexpression. LB1319-MEL cells were untreated or
treated with TatC3 exoenzyme (TatC3) 10µg/mL for 24 h (A,B).
LB1319-MEL cells were transfected with control siRNA (siCtrl) (C–G), two
RhoA-specific siRNAs (siRhoA1, siRhoA2) (C), two RhoB-specific siRNAs
(siRhoB1, siRhoB2) (D), two RhoC-specific siRNAs (siRhoC1, siRhoC2)
(E), two Rac1-specific siRNAs (siRac1.1, siRac1.2) (F), or two
Cdc42-specific siRNAs (siCdc42.1, siCdc42.2) (G). LB1319-MEL cells
were treated or not with a Ras inhibitor, FTS, 50–100µM for 24 h (H,I).
MICA membrane expression was analyzed by flow cytometry 72 h after
transfection or 24 h after treatment. Representative illustrations of
untreated cells (black) and of treated cells (filled in gray) with Tat-C3
exoenzyme (A) or FTS (H) are shown. To evaluate membrane antigen
expression, the index of specific fluorescence (ISF) was calculated as
indicated in the Section “Materials and Methods.” Results are expressed
as mean±SD (error bars, n=3 experiments). *P < 0.5; **P <0.01;
***P <0.001 versus control condition using the Student t -test (B) or the
Tukey ANOVA test (C–I).
obtained results, illustrated in Figures 4F,G, show that atorvas-
tatin treatment enhanced phosphorylations of c-Jun N-terminal
kinases (JKN, spot 2 in Figures 4F,G) and especially the c-Jun
kinase on Serine 63 (c-Jun, spot 3 in Figures 4F,G). Atorvastatin
could therefore increase MICA expression via the Stress Activated
Protein Kinase/JNK (SAPK/JNK) pathway, as previously described
in human kidney endothelial cells (Holmen et al., 2007).
Altogether, these results show that PPARγ and SAPK/JNK
pathways are involved in the atorvastatin-induced MICA
overexpression.
DISCUSSION
Melanomas are immunogenic tumors, which express tumor anti-
gens and other molecules recognized by the effectors of innate and
adaptive immune responses. The current metastatic melanoma
immunotherapies have limited efficiency (Robert et al., 2011;
Brahmer et al., 2012). Therefore, new molecules to enhance the
immune response are still needed. Statins are well known for
their hypocholesterolemic effect, but retrospective studies have
shown that statins also have a protective effect against melanoma
development (Jacobs et al., 2011). We previously showed that
inhibitors of the mevalonate pathway, notably statins, favored
an anti-melanoma adaptive immune response (Tilkin-Mariame
et al., 2005; Sarrabayrouse et al., 2007, 2010). Here, we tested the
ability of statins to enhance the NK-dependent innate immune
response against human melanomas, particularly because these
innate immune responses are essential for the control of metastases
(Mehlen and Puisieux, 2006).
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FIGURE 4 | PPARγ and SAPK/JNK are involved in
atorvastatin-induced MICA overexpression. LB1319-MEL cells
were treated with DMSO or a PPARγ inhibitor, T0070907 25 nM for
24 h (A,B). LB1319-MEL cells were transfected with an empty
plasmid (Ctrl) or a plasmid encoding a PPARγ dominant negative
mutant (PPARγ DN) (C,D). MICA membrane expression was analyzed
24 h after treatment or transfection. Representative illustrations of
controlled cells (black) and treated cells (filled in gray) with T0070907
(A) or PPARγ DN (C) are shown. The ISF were calculated (B,D).
LB1319-MEL cells were transfected with Firefly Luc control plasmids
(pGL4.23-FLuc) or plasmid reporting the PPARγ PPRE activity
(pGL4.3xPPRE-FLuc) and these cells were untreated (H2O) or treated
with atorvastatin 5µM (Ator 5µM). Twenty-four hours later, luciferase
assays were performed (E). LB1319-MEL cells were untreated (H2O)
or treated with atorvastatin 5µM for 48 h and a Proteome Profiler
Array was performed to compare kinases phosphorylation (F,G). One,
two, and three correspond respectively to a reference spot (REF),
panJNK T182/Y185, T221/Y223 (panJNK), and c-Jun S63 (c-Jun)
phosphorylations (F). The densities of the signals were analyzed with
ImageJ software and the ratios of atorvastatin on untreated
conditions were calculated (G). Results are expressed as mean±SD
(error bars, n=3 experiments). *P <0.5; **P <0.01; ***P <0.001
versus control condition using the Student t -test (B,D) or the Tukey
ANOVA test (E,G).
In two human melanoma cell lines, we showed that statin treat-
ments were not toxic at the doses used and that they weakly and
reproducibly upregulated MICA expression, which is a critical
target for anti-tumor NK cells. Interestingly, this weak MICA over-
expression was able to enhance melanoma cell sensitivity to NK
cell lysis in vitro. Similarly, Zhang et al. (2009) showed that sodium
butyrate treatment of HeLa and HepG2 cells induced a weak
but significant MICA overexpression allowing NK cells induced-
death enhancement. Furthermore as previously described using
hydralazine and valproate treatment on epithelial cancer cell lines
(Chavez-Blanco et al., 2011), our treatment of melanoma cells with
statins induced MICA membrane overexpression without increas-
ing the level of soluble MICA avoiding tumor-induced suppression
of NK cytotoxicity against the tumor. Moreover, the efficacy of this
statin-induced MICA overexpression was quite obvious in our
in vivo experiments performed in nude mice. The innate immune
response of nude mice could be tested against human melanoma
cells because these mice have NK cells bearing NKG2D receptors,
which are able to recognize human antigens, like MICA (Cerwenka
and Lanier, 2001; Fuertes et al., 2008). In vivo experiments showed
that melanoma tumor growth, induced by subcutaneous injec-
tions of statin-pretreated melanoma cells, was strongly decreased
compared to the tumors induced by untreated melanoma cells.
Furthermore two mice out of six completely rejected atorvastatin
pretreated tumor cells. Most importantly, statin pretreatment
also induced a significant decrease in melanoma metastatic lung
implantation and a highly significant modification and decrease
of the neoangiogenesis of these lungs. These modifications were
detected by IntegriSense fluorescence, which recognize αvβ3 inte-
grins overexpressed in the lungs during cancer cells colonization
(Kimura et al., 2009; Mery et al., 2011; He et al., 2012; Val-
divia et al., 2012). In vitro tumor migration is not affected by
atorvastatin treatment (Figures A2D,E in Appendix) therefore
NK-killing of MICA overexpressing melanoma cells seem to be
determinant for the reduction of melanoma development in vivo,
as suggested by the differences of tumor growth between MICA
negative (LB583-MEL and LB2033-MEL), MICA-low (untreated
LB1319-MEL), and MICA-higher (atorvastatin-treated LB1319-
MEL) melanoma cells.
These in vivo experiments could not be reproduced with the
BB74-MEL model because these cells did not form tumors in nude
mice. Two hypotheses could explain these results. The first is that
the in vitro proliferation rate of BB74-MEL cells (Figure A1D in
Appendix) is too slow compared to LB1319-MEL cells (Figure 1E).
As we followed the in vivo tumor growth of both cell lines for
the same amount of time, the BB74-MEL cells may not have had
enough time to form tumors. The second possible explanation is
that BB74-MEL cells could be rejected at once by the NK cells
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of the nude mice, because BB74-MEL cells express more MICA
than LB1319-MEL cells (Figure A4C in Appendix) and do not
express MHC class I molecules, which inhibit NK cells activity
(Figure A4D in Appendix).
In an effort to determine the mechanism of action of this
statin-induced MICA overexpression, we came to the unexpected
conclusion that it is not induced by members of the Ras super-
family. Experiments done with bacterial, biochemical inhibitors,
or siRNAs specific for Ras and Rho GTPases could not phenocopy
statin-induced MICA overexpression. However, two other statin-
altered pathways (Holmen et al., 2007; Balakumar and Mahade-
van, 2012) seem to be involved, namely PPARγ and SAPK/JNK.
Inhibitors of PPARγ factor induced a weak downregulation of
MICA expression, while treatment with atorvastatin increased the
activity of a synthetic promoter containing PPREs. Similarly, ator-
vastatin treatment also resulted in increased phosphorylation of
JNK and c-Jun. The respective roles of signaling pathways involv-
ing PPARγ and SAPK/JNK in melanoma development and in
MICA expression are still unknown and should be analyzed in
further studies.
In previous works, we showed that inhibitors of the Rho
GTPases favored adaptive anti-melanoma immune response
(Tilkin-Mariame et al., 2005; Sarrabayrouse et al., 2007, 2010).
In the present paper, we demonstrate that statins have another
beneficial role in modifying melanoma cells, which is to render
them more sensitive to the NK-killing. These results reinforce the
idea that statins could be effective drugs for an immuno-based
therapy of melanoma, by favoring adaptive and innate responses
as well as reducing the metastatic process.
MATERIALS AND METHODS
TUMOR CELL LINES AND ANIMALS
The human melanoma cell lines LB1319-MEL, BB74-MEL,
LB2033-MEL, and LB583-MEL were kindly provided by Pr.
T. Boon (Ludwig Institute for Cancer Research, Brussels).
They were maintained in culture by serial passages in culture
medium composed of RPMI 1640 medium (Lonza) supplemented
with 10% FCS, 1 mM glutamine, 1% penicillin-streptomycin-
amphotericinB (Lonza), and they were monthly tested to be
mycoplasma-free. Six- to nine-week-old female NMRI nude mice
were obtained from Elevages Janvier. The experiments in mice
have been done in the appropriate conditions of husbandry, exper-
imentation and care, controlled by the Ethic Comity of the Insti-
tut Claudius Regaud under the control of the Regional Comity
of Midi-Pyrénées (France). Our protocols were validated and
received the agreement number ICR-2009-0011.
TREATMENT OF MELANOMA CELLS
Melanoma cells were treated with a synthetic statin: atorvastatin
(Pfizer) at different doses from 0.3 to 10µM for 24 or 48 h, or a
natural statin: lovastatin (Calbiochem) at 1, 5, or 10µM for 48 h,
or a RhoA, B, and C inhibitor: Tat-C3 exoenzyme (produced in our
laboratory) (Sarrabayrouse et al., 2007) at 10µg/mL for 24 h, or
with a Ras inhibitor: S-FarneylThioSialicylic acid (Interchim) at
increasing concentrations from 50 to 100µM for 24 h, or a PPARγ
inhibitor: T0070907 (Calbiochem) at 25 nM for 24 h. Untreated
cells correspond to cells treated with equivalent volume of H2O
for atorvastatin, Ethanol (EtOH) for lovastatin, NaCl for Tat-C3
exoenzyme, DMSO for FTS and T0070907.
TRANSFECTION OF siRNAs OR PLASMIDS
Melanoma cells were transiently transfected with siRNAs as pre-
viously described (Sarrabayrouse et al., 2007). Briefly, 5× 105
cells were transfected with 20 nM of siRNAs using Oligofecta-
mine (Invitrogen). The siRNA duplexes were purchased from
Eurogentec: non-targeting siControl (siCtrl; GACGUGGGACUG-
AAGGGGU-TT), siRhoA1 (GAAGUCAAGCAUUUCUGUC-TT),
siRhoA2 (GCAGGUAGAGUUGGCUUUG-TT), siRhoB1 (CUAU-
GUGGGCCGACAUUGAG-TT), siRhoB2 (CCGUCUUCGAGAA-
CUAUGU-TT), siRhoC1 (UAAGAAGGACCUGAGGCAA-TT),




Melanoma cells were transiently transfected with a plasmid
encoding PPARγ dominant negative proteins. Briefly, 5× 105
cells were transfected with 500 ng of plasmids with JetPrime
(Invitrogen) according to the manufacturer’s instructions.
FLOW CYTOMETRY ANALYSES
Melanoma cells (1× 106) were stained with PE-conjugated anti-
MICA mAb and isotype control purchased from R&D Systems.
After 1 h incubation the stained cells were analyzed on a FACSCal-
ibur (Becton Dickinson) and the results were analyzed with FlowJo
software (Tree Star). To evaluate membrane antigen expression
on several independent experiments, the index of specific flu-
orescence (ISF) was determined. This was calculated using the
following formula:(
Median Fluorescence Intensity MFI with specific antibody
−MFI with isotype control)× 100
MFI with isotype control
(1)
WESTERN BLOT ANALYSES
Cells were lysed in lysis buffer (20 mM Tris pH 7.6, 150 mM
NaCl, 2 mM EDTA, 0.1% SDS, 0.5% NP-40, 1% proteases, and
phosphatases inhibitors cocktails) and protein extracts were pre-
pared by the standard procedure and then separated (50–200µg
protein/lane) on SDS-PAGE gels. Proteins were blotted onto
polyvinylidendifluoride membranes. The filters were incubated
at 4˚C overnight with primary antibodies against MICA (R&D
Systems). Actin was used as a loading control (Chemicon). The
membranes (Hybond-p, Amersham Biosciences) were then incu-
bated with HRP-labeled secondary antibody (Immunotech) for
1 h at room temperature (RT) and then detected by chemilumines-
cence detection kit (ECL, Pierce). Band intensities were quantified
using ImageJ software (National Institute of Health).
ELISA ASSAY
ELISA assays were performed using MICA DuoSet ELISA (R&D
Systems). Briefly, capture antibodies were coated onto 96-wells
plates overnight. Wells were washed and incubated with blocking
reagent for 1 h at RT. One hundred microliters of the supernatants
to be tested were added in triplicate for 2 h and detection anti-
body (in 2% goat serum; Lonza) was next incubated for 2 h at RT.
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One hundred microliters of Streptavidin-HRP were incubated for
20 min in the dark at RT and the reaction was revealed by TBM
(Thermo-Scientific) after 20 min in the dark at RT. The reaction
was stopped by addition of sulfuric acid 1 N. Optical density was
measured on a Labtech spectrophotometer at 450 nm.
NK CELLS ISOLATION
NK cells isolations were performed using CD49b (DX5)
MicroBeads (Miltenyi Biotec). Briefly, lymphocytes were isolated
from three C57BL/6 spleens. Lymphocytes were then labeled with
CD49b antibody coated with magnetic MicroBeads and applied
onto a column placed on a magnetic support. The column was
washed and unlabeled cells were collected. The CD49b-labeled
NK cells were collected with PBS after the column removal from
the magnetic support. NK cells purification was evaluated using
FITC-conjugated CD49b antibody (>90%).
ANALYSIS OF NK CELLS CYTOTOXIC ACTIVITY
We used Cytoxilux kit (Onco-immumin, Interchim) to investi-
gate NK cells cytotoxic activity by flow cytometry. Briefly 1× 106
LB1319-MEL cells pretreated either with H2O or 5µM atorvas-
tatin for 48 h were stained with targets marker TFL-4 (FL-4) for
20 min at 37˚C and then washed with PBS. Stained target cells were
then diluted at 8× 104 cells per 100µL of culture medium. The
effector NK cells (E) were incubated with the stained target cells
(T) for 1 h at 37˚C at 5:1 E/T ratio in 96-well plates (Dutscher) in
triplicate. Supernatant of each well was then discarded and 75µL
of caspase substrate, which is FITC fluorescent when cleaved (FL-
1) or 75µL of Wash Buffer for control conditions were added.
Cells were finally washed with Wash Buffer and resuspended in
PBS for analysis on a FACSCalibur. The percentage of cytotoxi-
city was calculated as the percentage of dead target cells, stained
both green (FL-1+) and blue (FL-4+), among the total number
of target cells (all FL-4+ cells).
SUBCUTANEOUS TUMOR GROWTH
To study the tumor growth, NMRI nude mice were injected
subcutaneously (s.c.) with 5× 106 LB1319-MEL cells or 2× 106
LB2033-MEL or LB583-MEL cells either untreated or pretreated
with 5µM atorvastatin for 48 h. The melanoma cells were washed
thrice in PBS before the injections to completely eliminate the
statin. Animals were monitored for tumor growth every 2–3 days
by palpation and diameters of the tumors were measured using
a Vernier caliper. Tumor-bearing animals were sacrificed at day
15 or 22 after tumor injection. At this time no mice were died
and the tumors did not display severe ulceration or reached a
size of 300 mm2. For the mice that had rejected the tumor cells,
experiments were terminated 9 weeks after tumor implantation.
Two groups of three mice were tested and the experiments were
done twice. Results are expressed as surface ±SD (error bars,
n= 6 mice). Statistical analysis was performed using a two-way
ANOVA test.
PULMONARY METASTASES IMPLANTATION
To study pulmonary metastases implantation, NMRI nude mice
were injected i.v. with 1× 106 LB1319-MEL cells either untreated
or pretreated 48 h with 5µM atorvastatin. The melanoma cells
were washed thrice in PBS before the injections to completely
eliminate the statin. These i.v. injections in the tail vein of
melanoma cells followed by lungs examination for tumor colo-
nization allows controlled and quantitative experimentation of the
last step of metastasis: the organ colonization. Mice were sacrificed
16 days later, at this time no mice were died. Mice were i.v. injected
with 100µL of IntegriSense (Perkin-Elmer) 30 h before sacrifice.
The fluorescence in the lungs was analyzed by Fluobeam®cam-
era (690–700 nm) for 120 ms exposition and the fluorescent sig-
nals were quantified using ImageJ software (National Institute of
Health). The experiments included three or four mice/group and
were done twice.
IN VITRO ASSAYS FOR CELL MIGRATION
The migration assay was performed with 8-µm pore size transwell
system (BD Biosciences). Cells (1× 104/well) were added with
serum-free medium in the upper compartment of the filter. The
bottom chamber was filled with complete medium. After 24 h, cells
on the bottom surface of the filter were stained and counted under
an Eclipse Ti microscope (Nikon Instruments; objective 20×) and
a CoolSNAP HQ2 camera (Photometrics) in three randomized
fields of 505 mm2.
LUCIFERASE ASSAYS
The reporter vector for PPARγ, pGL4.3xPPRE-FLuc plasmid con-
taining PPRE sequences, was homemade constructed from the
pB3xPPRE-Luc in an empty vector pGL4.23-FLuc (Rauwel et al.,
2010) expressing Firefly Luciferase (FLuc). The pGL4.3xPPRE and
the pGL4.23 were transfected using JetPrime (Invitrogen). The
pCMV-RLuc plasmid expressing Renilla Luciferase (RLuc) was
co-transfected as an internal control. Briefly, 3× 104 cells were
transfected with the reporter vectors as described above. Four
hours after, transfection was stopped by removing the medium
and cells were treated with H2O or atorvastatin. Twenty-four hours
later, luciferase activities were measured using the Dual Luciferase
Assay System (Promega).
REAL-TIME QUANTITATIVE PCR
Total RNA of LB1319-MEL cells untreated and treated with ator-
vastatin 5 or 10µM for 24 h were isolated using the RNeasy mini
kit (Qiagen) combined with the RNase-Free DNase set (Qia-
gen) according to the manufacturer’s instructions, then reverse-
transcribed using the iScript cDNA synthesis kit (BioRad). Quan-
titative real-time PCR was performed with a CFX96 Touch Real-
Time PCR detection system (BioRad) using iQ SYBR Green
Supermix (BioRad). We used β-actin as a housekeeping gene.
Primers sequences were: CPT1A forward 5′TCG-ATT-TTC-AAG-
GGT-CTT-CG3′, CPT1A reverse 5′CAC-AAC-GAT-CAG-CAA-
ACT-GG3′, β-actin forward 5′TCC-CTG-GAG-AAG-AGC-TAC-
GA3′, β-actin reverse 5′-AAG-GAA-GGC-TGG-AAG-AG3′. The
relative fold change was calculated using the following formula:
2−((Ct CPT1A−Ct β-actin) treated cells/(Ct CPT1A – Ct β-actin) untreated cells).
PROTEOME PROFILER ARRAY
Proteome Profiler Arrays were performed using Human Phospho-
Kinase Array Kit (R&D Systems). Briefly, 5× 105 LB1319-MEL
cells, either untreated (H2O) or treated with 5µM atorvas-
tatin, were lysed in the Lysis buffer. Supernatants were incu-
bated on the blocked membranes overnight at 4˚C. Membranes
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were washed and incubated with detection antibodies cocktails
for 2 h at RT. Membranes were washed and incubated with
1 mL of diluted Streptavidin-HRP for 30 min in the dark at RT.
Then the phospho-kinases were detected using chemilumines-
cence detection. Spot intensities were quantified using ImageJ
software (National Institute of Health).
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FIGURE A1 | Atorvastatin and lovastatin treatments of LB1319-MEL and
BB74-MEL cells induce MICA membrane overexpression. LB1319-MEL
cells were treated with increasing concentrations of atorvastatin and
membrane MICA expression was analyzed by flow cytometry (A). BB74-MEL
cells were treated with 5 or 10µM atorvastatin for 48 h (Ator) or untreated
(H2O). MICA membrane expression was analyzed by flow cytometry (B) and
cleavage by ELISA (C). **P < 0.01; ***P <0.001; versus control condition
using the Tukey ANOVA test. Every 2–3 days pretreated (Ator) and untreated
(H2O) BB74-MEL cells were counted to evaluate the in vitro proliferation (D).
ns; versus control condition using the two-way ANOVA test. LB1319-MEL
cells were treated with increasing concentrations of lovastatin and membrane
MICA expression was analyzed (E).
FIGURE A2 | Atorvastatin treatment had no effect on MICA
negative melanoma cell lines in vivo tumor growth and on in vitro
tumor migration. LB2033-MEL and LB583-MEL cells were treated
with increasing concentrations of atorvastatin for 48 h and MICA
membrane expression was analyzed by flow cytometry (A). ns; versus
control condition using the Tukey ANOVA test. LB2033-MEL and
LB583-MEL cells untreated (H2O) or pretreated with atorvastatin 5µM
for 48 h (Ator) were injected subcutaneously into the flank of nude
mice. Tumor growth was measured every 2–3 days (B,C). ns; versus
control condition using the two-way ANOVA test. In vitro migration of
LB1319-MEL cells untreated (H2O) or pretreated with atorvastatin 5µM
for 48 h (Ator) was analyzed using transwell assays (D). ns; versus
control condition using the Student t -test. Images are representative of
the migrating cells (E).
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A B C D E
FIGURE A3 | Decrease of Rho proteins expression in LB1319-MEL cells
transfected with Rho specific siRNAs. The efficiency in decreasing Rho
protein expression of Rho specific siRNAs transfections were analyzed by
western blot, and actin was used as a control of a uniform loading. RhoA,
RhoB, RhoC, Rac1, and Cdc42 expressions were analyzed to test their
respective specific siRNAs efficiencies (A–E).
A B
C D
FIGURE A4 | Activation of PPARγ pathway by increasing doses of
atorvastatin and MICA and MHC class I expression in LB1319-MEL
versus BB47-MEL cell lines. LB1319-MEL cells were transfected with
Firefly Luc control plasmids (pGL4.23-FLuc) or plasmid reporting the PPARγ
PPRE activity (pGL4.3xPPRE-FLuc) and these cells were untreated (H2O) or
treated with increasing doses of atorvastatin from 0.3 to 10µM. Twenty-four
hours later, luciferase assays were performed (A). LB1319-MEL cells were
treated with 5 or 10 µM atorvastatin for 24 h or untreated (H2O) and CPT1A
mRNA relative expression, normalized by β-actin, was detected by RT-qPCR
(B). Results are expressed as mean±SD (error bars, n=3 experiments).
*P <0.5; **P <0.01; ***P <0.001 versus control condition using the Tukey
ANOVA test (A,B). Expressions of MICA (C), and MHC class I molecules (D)
were compared between LB1319-MEL and BB74-MEL cell lines by flow
cytometry.
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